AdaptHealth Corp vs Invesco S&P 500 Momentum ETF — how do they compare? AdaptHealth Corp trades at $5.65 (market cap $753.09M), while Invesco S&P 500 Momentum ETF trades at $150.09. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.
| AHCO | SPMO | |
|---|---|---|
Market Cap | $753.09M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $13.38 | $161.66 |
52-Week Low | $5.22 | $107.84 |
Enterprise Value | $2.77B | — |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth Corp. (AHCO) trades at $5.69, down 5.87% in the last 24 hours, reflecting negative sentiment after recent earnings misses and lowered guidance. The stock shows a bearish technical signal with support near $5, while fundamentals reveal revenue of $3.24 billion in 2025 but a net loss of $70.79 million, with profitability metrics like net margin at -6.82% indicating operational challenges. Recent news highlights multiple law firm investigations into potential securities fraud following disappointing Q2 2026 results.
The outlook for AHCO is cautious due to persistent earnings underperformance and rising costs from fixed-price contracts. While analyst consensus remains bullish with a $11.00 price target, significant risks include ongoing legal scrutiny, margin pressure, and execution uncertainties. Investors should weigh the high institutional buy ratings against fundamental weaknesses and recent negative developments.
SPMO (Invesco S&P 500 Momentum ETF) trades at $149.69, up 0.4% with strong bullish momentum indicators. The ETF has demonstrated exceptional 2026 performance with 26% returns, significantly outperforming the S&P 500 while maintaining lower drawdowns. Technical analysis shows bullish moving averages but neutral oscillators, with RSI_6 at 88.22 suggesting potential overbought conditions. Recent institutional interest includes Alpha Zero LLC increasing its position by 6.4% to $10.73 million in Q1 2026.
The outlook remains positive given SPMO's momentum-driven strategy and concentrated tech exposure (55% weighting), particularly benefiting from AI-driven growth. However, risks include higher volatility during sector rotations and downside vulnerability if momentum factors reverse. The ETF's 0.13% expense ratio provides cost efficiency for momentum exposure, but investors should monitor concentration risks in technology holdings.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →